Apollomics announces two new cohorts in global phase 2 sparta study of vebreltinib in non-small cell lung cancer and other solid tumors with met dysregulation

Foster city, calif., oct. 31, 2023 (globe newswire) -- apollomics inc. (nasdaq: aplm), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the addition of two new cohorts in its ongoing global multi-cohort phase 2 sparta study (nct03175224), which is evaluating vebreltinib (apl-101) in patients with non-small cell lung cancer (nsclc) and other solid tumors (i.e., brain, esophageal, colon, pancreatic cancer) with met dysregulations, including exon14 skipping mutation, c-met amplification and met fusion.
APLM Ratings Summary
APLM Quant Ranking